A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.

Time frame

0 - 52 weeks.

Measure

MEAN · units on a scale

Reporting status

POSTED

Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = "best possible" and 10 = "worst possible". A negative value indicates an improvement in score from baseline.

Population: All subjects who entered the study from a central neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

0 - 52 weeks.

Measure

MEAN · units on a scale

Reporting status

POSTED

Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = "best possible" and 10 = "worst possible". A negative value indicates an improvement in score from baseline.

Population: All subjects who entered the study from a neuropathic pain in multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

0 - 52 weeks.

Measure

MEAN · units on a scale

Reporting status

POSTED

Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = "best possible" and 10 = "worst possible". A negative value indicates an improvement in score from baseline.

Population: All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.

Population: All multiple sclerosis subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.

Population: All multiple sclerosis subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.

Population: All subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051days

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.

Population: All subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.

Population: All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.

Population: All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.

Population: All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days.

Measure

NUMBER · participants

Reporting status

POSTED

Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.

Population: All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days

Measure

NUMBER · participants

Reporting status

POSTED

Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of "much worse", "worse", "no change", "better", "much better". The number of subjects rated by the investigator as "better" or "much better" at the last study visit is presented.

Population: All subjects who entered the study from a parent RCT investigation neuropathic pain due to multiple sclerosis, and who received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days.

Measure

NUMBER · participants

Reporting status

POSTED

Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of "much worse", "worse", "no change", "better", "much better". The number of subjects rated by the investigator as "better" or "much better" at the last study visit is presented.

Population: All subjects who entered the study from a central neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days.

Measure

NUMBER · participants

Reporting status

POSTED

Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of "much worse", "worse", "no change", "better", "much better". The number of subjects rated by the investigator as "better" or "much better" at the last study visit is presented.

Population: All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.

Time frame

Up to 1051 days.

Measure

NUMBER · participants

Reporting status

POSTED

Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of "much worse", "worse", "no change", "better", "much better". The number of subjects rated by the investigator as "better" or "much better" at the last study visit is presented.

Population: All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.